Cargando…

Detecting and Locating the Site of Local Relapse Using (18)F-PSMA-1007 Imaging After Primary Treatment of 135 Prostate Cancer Patients—Potential Impact on PSMA-Guided Radiation Therapy

PURPOSE: Due to limited imaging options, the visualization of a local relapse of prostate cancer used to pose a considerable challenge. However, since the integration of (18)F-PSMA-1007-PET/CT into the clinic, a relapsed tumor can now easily be detected by hybrid imaging. The present study aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koerber, S. A., Kroener, R. C., Dendl, K., Kratochwil, C., Fink, C. A., Ristau, J., Winter, E., Herfarth, K., Hatiboglu, G., Hohenfellner, M., Haberkorn, U., Debus, J., Giesel, F. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006015/ https://www.ncbi.nlm.nih.gov/pubmed/35999425 http://dx.doi.org/10.1007/s11307-022-01766-6

Ejemplares similares

Predicting the Risk of Metastases by PSMA-PET/CT—Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma
por: Koerber, Stefan A., et al.
Publicado: (2021)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
por: Stefan A. Koerber, et al.
Publicado: (2020)

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology?
por: König, Laila, et al.
Publicado: (2017)

Diagnostic Accuracy of (18)F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
por: Sprute, Katharina, et al.
Publicado: (2021)

F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
por: Giesel, Frederik L., et al.
Publicado: (2016)

PSMA-1007 Uptake in Ganglia of the Sympathetic Trunk and Its Intra-individual Reproducibility
por: Mamlins, E., et al.
Publicado: (2022)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
por: Giesel, Frederik L., et al.
Publicado: (2019)

Preclinical comparative study of [(18)F]AlF-PSMA-11 and [(18)F]PSMA-1007 in varying PSMA expressing tumors
por: Piron, Sarah, et al.
Publicado: (2022)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer
por: Giesel, F. L., et al.
Publicado: (2016)

PSMA-Positive Low Malignant Gastrointestinal Stromal Tumor in the Stomach on F-18-PSMA-1007 PET/CT
por: Iversen, Peter, et al.
Publicado: (2022)

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617
por: Kratochwil, Clemens, et al.
Publicado: (2017)

Automated [(18)F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination
por: Naka, Sadahiro, et al.
Publicado: (2020)

(68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients
por: Sterzing, Florian, et al.
Publicado: (2015)

Integration of CT urography improves diagnostic confidence of (68)Ga-PSMA-11 PET/CT in prostate cancer patients
por: Will, Leon, et al.
Publicado: (2017)

Biokinetics and dosimetry of (18)F‐PSMA‐1007 in patients with prostate cancer
por: Hvittfeldt, Erland, et al.
Publicado: (2022)

Skeletal (18)F-PSMA-1007 uptake in prostate cancer patients
por: Janssen, Jorinde, et al.
Publicado: (2023)

Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT
por: Koerber, Stefan A., et al.
Publicado: (2021)

Intra-Individual Comparison of Physiologic [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 Uptake in Ganglia in Patients with Prostate Cancer: A Retrospective, Monocentric Analysis
por: Novruzov, Emil, et al.
Publicado: (2023)

Impact of Primary Staging with Fibroblast Activation Protein Specific Enzyme Inhibitor (FAPI)-PET/CT on Radio-Oncologic Treatment Planning of Patients with Esophageal Cancer
por: Ristau, J., et al.
Publicado: (2020)

Total Tumor Volume on (18)F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with (225)Ac-PSMA-I&T
por: Unterrainer, Lena M., et al.
Publicado: (2022)

(18)F-PSMA-1007 PET/CT uptake in multiple angiolipomas caused by PSMA expression in capillaries: a case report
por: Wang, Long, et al.
Publicado: (2021)

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2018)

PSMA-GCK01: A Generator-Based (99m)Tc/(188)Re Theranostic Ligand for the Prostate-Specific Membrane Antigen
por: Cardinale, Jens, et al.
Publicado: (2023)

FAP imaging in rare cancer entities—first clinical experience in a broad spectrum of malignancies
por: Dendl, K., et al.
Publicado: (2021)

Distinguishing Benign and Malignant Findings on [(68) Ga]-FAPI PET/CT Based on Quantitative SUV Measurements
por: Dabir, M., et al.
Publicado: (2022)

Development and dosimetry of (203)Pb/(212)Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
por: dos Santos, José Carlos, et al.
Publicado: (2019)

Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET/CT
por: Dendl, Katharina, et al.
Publicado: (2021)

High detection rate in [(18)F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients
por: Watabe, Tadashi, et al.
Publicado: (2021)

PSMA ligands for diagnosis and therapy of prostate cancer
por: Haberkorn, Uwe
Publicado: (2014)

Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on (18)F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
por: Zhang, Yan-Nan, et al.
Publicado: (2022)

PSMA Theranostics: Science and Practice
por: Mokoala, Kgomotso, et al.
Publicado: (2021)

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

A randomised, prospective and head-to-head comparison of [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT—Protocol design and rationale
por: Alberts, Ian, et al.
Publicado: (2022)

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kci7s314tjsvj1iqcvtibi4j1s